[Clinical characteristics and treatment response in adult patients with non-Hodgkin's chronic lymphocytic leukemia (CLL)].
نویسندگان
چکیده
OBJECTIVE To determine comorbidities, clinical characteristics, and treatment response in adult patients with chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). METHODS The design was observational from reviewing the medical records of patients seen in outpatient and inpatient settings. It included ≥50 subjects who demanded attention during the period 2008-2012 and that met specific inclusion/exclusion criteria. The main measures were: comorbidity (population group), clinical stage, patient treatment, response to treatment, overall survival, progression-free survival, and mortality. STATISTICAL ANALYSIS p<0.05. RESULTS 270 patients (CLL=90, DLBCL=81, FL=99) were recruited, with a mean age of 72.5, 65.5, and 62.4 years, respectively. These groups of neoplasms, compared with the general population, showed a higher percentage of men (60.0, 56.8 and 52.6 vs. 46.2%) and morbidity (Charlson Comorbidity Index: 1.6, 1.5, 1.4 vs. 0.4, respectively; p<0.05). The administration of chemotherapy treatment was 28.9 vs. 86.4 and 90.9%, respectively (p<0.001). Overall survival at five years was 84.4, 45.0 and 68.5%, respectively (p=0.027), while mortality rates were 17.0 vs. 35.3 and 20.6%, respectively (p=0.041). Compared with other treatments, with administered rituximab the median progression-free survival was 6.8 vs. 4.2 years (p<0.001). These differences were maintained for the three neoplasms. CONCLUSIONS Comorbidity associated with hematological malignancies is high. The chronic lymphocytic leukemia group showed increased survival with lower mortality rate. Rituximab showed a higher progression-free survival in these neoplasms.
منابع مشابه
Expression Profiles of miR-93 and miR-330 in Iranian Patients with Chronic Lymphocytic Leukemia
Background and Aims: Chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. Research has shown that in CLL, microRNAs can have function as oncogenes or tumor suppressors. Some studies demonstrated that the expression of microRNA-93 (miR-93) and microRNA-330 (miR-330) have been changed in several can...
متن کاملChronic lymphocytic leukemia, biology, new diagnosis and treatment: review article
Chronic lymphocytic leukemia (CLL) is a malignancy of B CD5+cells and is the most common type of leukemia in adults. The disease is more common in men over 50 years in western countries. CLL is associated with defective apoptosis in B cells. CLL was traditionally regarded as a disease that occurs before naïve B cells meet the antigen in the lymph nodes. Laboratory diagnosis requires white blood...
متن کاملEffect of curcumin on growth inhibition and gene expression reduction in chronic lymphocytic leukemia cells (CLL-CII)
Introduction: Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults living in Western countries. with a diverse clinical course that due to life expectancy less than two years between patients finding ,new therapeutic strategies is essential for it. Curcumin as the biologic active of turmeric, has many biological properties such as anti-inflammatory, anti-oxidant, anti-diab...
متن کاملAssociation between rs 1800561 CD38 Gene Polymorphism and Chronic Lymphocytic Leukemia Risk
Background and purpose: Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia characterized by the accumulation of seemingly mature type B lymphocytes in peripheral blood and lymphatic organs. One of the main markers used in the diagnosis and prognosis of CLL is the CD38 gene. Polymorphism is considered to be a major genetic source of phenotypic change within a species an...
متن کاملDown-regulation of miR-193b-3p and miR-376a-3p in Chronic Lymphocytic Leukemia
Background: Chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. Studies revealed that microRNAs (miRNAs) can function as oncogenes or tumor suppressors in CLL and that the expression of miRNAs, such as miR-193b-3p and miR-376a-3p change in several diseases. We aimed to elucidate the changes in miR-193b-3p and miR-376a-3p expression in CLL and determine their potential as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Gaceta medica de Mexico
دوره 152 1 شماره
صفحات -
تاریخ انتشار 2016